Varaico: Literature-Extracted Genetic Variants

Gene:GLA
Variant:p.M96I
Back to variants list

GLA

NM_000169.3:p.M96I

Associated Papers

Clinical characteristics and interdepartmental collaboration for patients with Anderson-Fabry disease in Shiga Prefecture, Japan.

Tomioka D et al.

Molecular Genetics and Metabolism Reports, 2025

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.

Hughes DA et al.

Journal of Medical Genetics, 2023

36543533 (PubMed )
Supplement: jmg-2022-108669supp001.pdf

Population Frequency of Undiagnosed Fabry Disease in the General Population.

Kermond-Marino A et al.

Kidney International Reports, 2023

37441486 (PubMed )
Supplement: mmc1.pdf

Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.

Kume S et al.

Internal Medicine (tokyo, Japan), 2022

Inherited Metabolic Diseases and Cardiac Pathology in Adults: Diagnosis and Prevalence in a CardioMetabo Study.

Brailova M et al.

Journal of Clinical Medicine, 2020

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.

Narita I et al.

Clinical and Experimental Nephrology, 2020

Magnetic Resonance Imaging Findings Related to Stroke Risk in Japanese Patients With Fabry Disease.

Yagita Y et al.

Stroke, 2019

31337300 (PubMed )
Supplement: str_stroke-2019-025528_supp1.pdf

Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.

Kobayashi M et al.

Journal of Human Genetics, 2019

Fabry disease in a Japanese population-molecular and biochemical characteristics.

Sakuraba H et al.

Molecular Genetics and Metabolism Reports, 2018

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017

27657681 (PubMed )
Supplement: gim2016122x1.zip › Supplemental_Appendix_2_12152015.xlsx › Unknown

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Hughes DA et al.

Journal of Medical Genetics, 2017

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease.

Tsukimura T et al.

Molecular Genetics and Metabolism Reports, 2014

[Molecular genetics of Fabry disease].

Sakuraba H

Seikagaku. the Journal of Japanese Biochemical Society, 1989

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."